The 2018 U.S. Farm Bill protects a particular set of cannabinoids – the chemical compounds derived from the hemp variety of the Cannabis sativa plant. These cannabinoids are legal as long as federal and state regulations are adhered to. The most famous of these cannabinoids is CBD and of late, so is delta-8 THC. Although legal, it’s important for consumers to be aware that delta-8 THC products have not been evaluated or approved by the FDA.
CannabizMD Founder/CEO Jacquie Cohen Roth, MS, moderates the webinar “Innovation or Danger: Hemp-Derived Cannabinoids + Delta 8” with cannabis industry for a discussion with cannabis industry experts Matthew Mintz, MD, FACP, Dr. Linda Klumpers, PhD, and Matthew S Schweber exploring hemp-derived cannabinoids including their potential as a wellness product and disease treatment. From a legal perspective, delta-8 is in a gray area and is challenging the industry of what is legal at the federal level and at the state level. From a healthcare provider perspective, it can be a therapeutic option for patients, but many don’t know about it or understand it. From a consumer perspective, delta-8 has exploded on the scene as a legal hemp-based product that is sold everywhere, including your gas station, but with very little oversight or quality testing standards. From a cannabis industry perspective, is this an opportunity for innovation, for new research or product development, creation of industry best standards? Absolutely. Or is it a threat?
Click through the photo to view the webinar recording. Visit and subscribe to the CannabizMD YouTube channel for more webinar recordings.
